Targeting inhibitory pathways in cancer immunotherapy

Current Opinion in Immunology

Volumn 22, Issue 3, 2010, Pages 385-390

  Lasaro, Marcio O ^a   Ertl, Hildegund C J ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HEPATITIS B SURFACE ANTIGEN; PROVENGE; TUMOR ANTIGEN; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOSTIMULATION; INNATE IMMUNITY; LIVER CELL CARCINOMA; LYMPHOCYTE FUNCTION; NEOPLASM; NONHUMAN; PROSTATE CANCER; PROTEIN DOMAIN; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSGENE; TUMOR GROWTH; UPREGULATION; UTERINE CERVIX CANCER; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NEOPLASMS; PROCEDURES; TUMOR ESCAPE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; TUMOR ESCAPE;

EID: 77953537927     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.04.005     Document Type: Review

References (65)

1. Parmiani G., De Filippo A., Novellino L., Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 2007, 178:1975-1979.
2. Lizee G., Cantu M.A., Hwu P. Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin Cancer Res 2007, 13:5250-5255.
3. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005, 23:2346-2357.
4. Chang M.H., You S.L., Chen C.J., Liu C.J., Lee C.M., Lin S.M., Chu H.C., Wu T.C., Yang S.S., Kuo H.S., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355.
5. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369:1861-1868.
6. Drake C.G. Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol 2009, 27:4035-4037.
7. Schuster S.J., Neelapu S.S., Gause B.L., Muggia F.M., Gockerman J.P., Sotomayor E.M., Winter J.N., Flowers C.R., Stergiou A.M., Kwak L.W., et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. J Clin Oncol (Meeting Abstracts) 2009, 27:2.
8. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Essahsah F., Fathers L.M., Offringa R., Drijfhout J.W., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
9. McMahan R.H., Slansky J.E. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol 2007, 17:317-329.
10. Coscoy L. Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat Rev Immunol 2007, 7:391-401.
11. Peggs K.S., Quezada S.A., Allison J.P. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008, 224:141-165.
12. Lazar-Molnar E., Hegyesi H., Toth S., Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000, 12:547-554.
13. Ohm J.E., Carbone D.P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001, 23:263-272.
14. Ruiz-Cabello F., Nevot M.A., Garrido F. MHC class I and II gene expression on human tumors. Adv Exp Med Biol 1988, 233:119-128.
15. Seliger B., Maeurer M.J., Ferrone S. TAP off-tumors on. Immunol Today 1997, 18:292-299.
16. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009, 15:513-520.
17. Whiteside T.L. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 2002, 12:43-50.
18. Seliger B., Marincola F.M., Ferrone S., Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008, 14:550-559.
19. Piersma S.J., Welters M.J., van der Burg S.H. Tumor-specific regulatory T cells in cancer patients. Hum Immunol 2008, 69:241-249.
20. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003, 77:4911-4927.
21. Wick M., Dubey P., Koeppen H., Siegel C.T., Fields P.E., Chen L., Bluestone J.A., Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997, 186:229-238.
22. Kathryn M., Alan R.C. New approaches for modelling cancer mechanisms in the mouse. J Pathol 2005, 205:181-193.
23. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004, 16:143-150.
24. Draper S.J., Heeney J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8:62-73.
25. Itoh K., Yamada A., Mine T., Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol 2009, 39:73-80.
26. Mohebtash M., Gulley J.L., Madan R.A., Ferrara T., Arlen P.M. Cancer vaccines: current directions and perspectives in prostate cancer. Curr Opin Mol Ther 2009, 11:31-36.
27. Murthy V., Moiyadi A., Sawant R., Sarin R. Clinical considerations in developing dendritic cell vaccine based immunotherapy protocols in cancer. Curr Mol Med 2009, 9:725-731.
28. Jinushi M., Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci 2009, 100:1389-1396.
29. Baxevanis C.N., Perez S.A., Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 2009, 58:317-324.
30. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007, 117:1167-1174.
31. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu Rev Immunol 2005, 23:515-548.
32. Keir M.E., Francisco L.M., Sharpe A.H. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007, 19:309-314.
33. van Berkel M.E., Oosterwegel M.A. CD28 and ICOS: similar or separate costimulators of T cells?. Immunol Lett 2006, 105:115-122.
34. Yi K.H., Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 2009, 229:145-151.
35. Sarnaik A.A., Weber J.S. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 2009, 15:169-173.
36. Wong R.M., Scotland R.R., Lau R.L., Wang C., Korman A.J., Kast W.M., Weber J.S. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 2007, 19:1223-1234.
37. del Rio M.L., Lucas C.L., Buhler L., Rayat G., Rodriguez-Barbosa J.I. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J Leukoc Biol 2009, 87:223-235.
38. Sedy J.R., Gavrieli M., Potter K.G., Hurchla M.A., Lindsley R.C., Hildner K., Scheu S., Pfeffer K., Ware C.F., Murphy T.L., et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005, 6:90-98.
39. Tao R., Wang L., Murphy K.M., Fraser C.C., Hancock W.W. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol 2008, 180:6649-6655.
40. Cai G., Anumanthan A., Brown J.A., Greenfield E.A., Zhu B., Freeman G.J. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol 2008, 9:176-185.
41. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., Betts M.R., Freeman G.J., Vignali D.A., Wherry E.J. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009, 10:29-37.
42. Lasaro M.O., Tatsis N., Hensley S.E., Whitbeck J.C., Lin S.W., Rux J.J., Wherry E.J., Cohen G.H., Eisenberg R.J., Ertl H.C. Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med 2008, 14:205-212.
43. Montgomery R.I., Warner M.S., Lum B.J., Spear P.G. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996, 87:427-436.
44. Fridlender Z.G., Buchlis G., Kapoor V., Cheng G., Sun J., Singhal S., Crisanti C., Wang L.C., Heitjan D., Snyder L.A., et al. CCL2 blockade augments cancer immunotherapy. Cancer Res 2010, 70:109-118.
45. Rech A.J., Vonderheide R.H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009, 1174:99-106.
46. Ruter J., Barnett B.G., Kryczek I., Brumlik M.J., Daniel B.J., Coukos G., Zou W., Curiel T.J. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci 2009, 14:1761-1770.
47. McElhaney J.E., Effros R.B. Immunosenescence: What does it mean to health outcomes in older adults?. Curr Opin Immunol 2009, 21:418-424.
48. Ginaldi L., De Martinis M., D'Ostilio A., Marini L., Loreto M.F., Corsi M.P., Quaglino D. The immune system in the elderly: I. Specific humoral immunity. Immunol Res 1999, 20:101-108.
49. Aydar Y., Balogh P., Tew J.G., Szakal A.K. Follicular dendritic cells in aging, a " bottle-neck" in the humoral immune response. Ageing Res Rev 2004, 3:15-29.
50. Zheng B., Han S., Takahashi Y., Kelsoe G. Immunosenescence and germinal center reaction. Immunol Rev 1997, 160:63-77.
51. Eaton S.M., Burns E.M., Kusser K., Randall T.D., Haynes L. Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J Exp Med 2004, 200:1613-1622.
52. Lazuardi L., Jenewein B., Wolf A.M., Pfister G., Tzankov A., Grubeck-Loebenstein B. Age-related loss of naive T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology 2005, 114:37-43.
53. Yang X., Stedra J., Cerny J. Relative contribution of T and B cells to hypermutation and selection of the antibody repertoire in germinal centers of aged mice. J Exp Med 1996, 183:959-970.
54. Effros R.B., Walford R.L. The immune response of aged mice to influenza: diminished T-cell proliferation, interleukin 2 production and cytotoxicity. Cell Immunol 1983, 81:298-305.
55. Franceschi C., Bonafe M., Valensin S. Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine 2000, 18:1717-1720.
56. Yager E.J., Ahmed M., Lanzer K., Randall T.D., Woodland D.L., Blackman M.A. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med 2008, 205:711-723.
57. Shimada Y., Hayashi M., Nagasaka Y., Ohno-Iwashita Y., Inomata M. Age-associated up-regulation of a negative co-stimulatory receptor PD-1 in mouse CD4+ T cells. Exp Gerontol 2009, 44:517-522.
58. Channappanavar R., Twardy B.S., Krishna P., Suvas S. Advancing age leads to predominance of inhibitory receptor expressing CD4 T cells. Mech Ageing Dev 2009, 130:709-712.
59. DiMenna L, Latimer B, Parzych E, Haut L, Töpfer K, Abdulla S, Yu H, Manson B, Giles-Davis W, Zhou D, et al.: Augmentation of primary influenza A virus specific CD8+ T cell responses in aged mice through blockade of an immunoinhibitory pathway. J Immunol, in press, 2010, doi:10.4049/jimmunol.0903808.
60. Gregg R., Smith C.M., Clark F.J., Dunnion D., Khan N., Chakraverty R., Nayak L., Moss P.A. The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin Exp Immunol 2005, 140:540-546.
61. Hwang K.A., Kim H.R., Kang I. Aging and human CD4(+) regulatory T cells. Mech Ageing Dev 2009, 130:509-517.
62. Grosso J.F., Kelleher C.C., Harris T.J., Maris C.H., Hipkiss E.L., De Marzo A., Anders R., Netto G., Getnet D., Bruno T.C., et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007, 117:3383-3392.
63. Lasaro M.O., Ertl H.C. Potentiating vaccine immunogenicity by manipulating the HVEM/BTLA pathway and other co-stimulatory and co-inhibitory signals of the immune system. Hum Vaccine 2009, 5:6-14.
64. Korman A.J., Peggs K.S., Allison J.P. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006, 90:297-339.
65. Zou W., Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008, 8:467-477.